Bharath Rajagopalan1, Christopher Madias2. 1. The Cardiovascular Center, Tufts Medical Center, Boston, MA, 02111, USA. 2. The Cardiovascular Center, Tufts Medical Center, Boston, MA, 02111, USA. cmadias@tuftsmedicalcenter.org.
Abstract
PURPOSE OF REVIEW: The choice of appropriate antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary interventions (PCI) should be approached prudently. Careful consideration is necessary, balancing the ischemic and bleeding risk. Traditionally, triple antithrombotic therapy comprising of aspirin, a P2Y12 inhibitor, and an oral anticoagulant is associated with high bleeding rates. RECENT FINDINGS: Recent trials have evaluated the safety and effectiveness of dual antithrombotic therapy in AF patients undergoing PCI. These studies have shown a significant reduction in bleeding with no increase in ischemic events. Clopidogrel is the preferred P2Y12 agent in the dual antithrombotic regimens. The novel oral anticoagulants (NOAC) rivaroxaban and dabigatran have been evaluated as part of dual antithrombotic therapy and are preferred options for oral anticoagulation in AF patients undergoing PCI. Studies are in progress to evaluate the role of alternate NOACs in this clinical scenario. This review explores the contemporary management of antithrombotic therapy in AF patients undergoing PCI.
PURPOSE OF REVIEW: The choice of appropriate antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary interventions (PCI) should be approached prudently. Careful consideration is necessary, balancing the ischemic and bleeding risk. Traditionally, triple antithrombotic therapy comprising of aspirin, a P2Y12 inhibitor, and an oral anticoagulant is associated with high bleeding rates. RECENT FINDINGS: Recent trials have evaluated the safety and effectiveness of dual antithrombotic therapy in AFpatients undergoing PCI. These studies have shown a significant reduction in bleeding with no increase in ischemic events. Clopidogrel is the preferred P2Y12 agent in the dual antithrombotic regimens. The novel oral anticoagulants (NOAC) rivaroxaban and dabigatran have been evaluated as part of dual antithrombotic therapy and are preferred options for oral anticoagulation in AFpatients undergoing PCI. Studies are in progress to evaluate the role of alternate NOACs in this clinical scenario. This review explores the contemporary management of antithrombotic therapy in AFpatients undergoing PCI.
Authors: Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting Journal: J Am Coll Cardiol Date: 2011-11-07 Impact factor: 24.094
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg Journal: Lancet Date: 2013-02-13 Impact factor: 79.321
Authors: Tuomas Kiviniemi; Marja Puurunen; Axel Schlitt; Andrea Rubboli; Pasi Karjalainen; Saila Vikman; Matti Niemelä; Heli Lahtela; Gregory Y H Lip; K E Juhani Airaksinen Journal: Am J Cardiol Date: 2014-04-01 Impact factor: 2.778
Authors: Morten Lamberts; Gunnar H Gislason; Jonas Bjerring Olesen; Søren Lund Kristensen; Anne-Marie Schjerning Olsen; Anders Mikkelsen; Christine Benn Christensen; Gregory Y H Lip; Lars Køber; Christian Torp-Pedersen; Morten Lock Hansen Journal: J Am Coll Cardiol Date: 2013-06-07 Impact factor: 24.094
Authors: S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf Journal: Lancet Date: 2006-06-10 Impact factor: 79.321
Authors: Juan M Ruiz-Nodar; Francisco Marín; Vanessa Roldán; José Valencia; Sergio Manzano-Fernández; Luis Caballero; José A Hurtado; Francisco Sogorb; Mariano Valdés; Gregory Y H Lip Journal: Circ Cardiovasc Interv Date: 2012-07-10 Impact factor: 6.546
Authors: Juan M Ruiz-Nodar; Francisco Marín; José Antonio Hurtado; José Valencia; Eduardo Pinar; Javier Pineda; Juan Ramón Gimeno; Francisco Sogorb; Mariano Valdés; Gregory Y H Lip Journal: J Am Coll Cardiol Date: 2008-02-26 Impact factor: 24.094